Molecular Immunology Laboratory, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, India.
Immunohorizons. 2024 Aug 1;8(8):511-526. doi: 10.4049/immunohorizons.2400055.
Glycoconjugate vaccines elicit robust anti-polysaccharide Ab response by recruiting T-cell help. Multiple doses of glycoconjugate vaccine are required to induce long-lasting immunity. The characteristics of anti-polysaccharide Ab response have been reported previously. However, the effect of glycoconjugate booster immunization on anti-polysaccharide and anti-carrier protein Ab repertoire remains poorly understood. In this study, we used clinically relevant pneumococcal capsular polysaccharide type 14 (PCP14) conjugated with cross-reactive material 197 (CRM197) as a model glycoconjugate Ag (PCP14-CRM197). We performed a comprehensive sequence analysis of mouse mAbs generated against PCP14 and CRM197 following immunization with one or three doses of PCP14-CRM197. Analysis of the paired Ig H and L chain transcripts revealed that anti-PCP14 Ab repertoire is extremely restricted. The reoccurrence of five replacement mutations at identical positions in anti-polysaccharide mAbs generated from different mice provided evidence for Ag-driven selection in PCP14-specific B cells. Convergent evolution was observed wherein distinct V(D)J rearrangements resulted in identical or nearly identical CDR3 in anti-PCP14 mAbs. Abs that lacked DH encoded amino acids dominated the anti-PCP14 Ab response. In contrast, anti-CRM197 Ab response was quite diverse, with fewer mutations compared with the anti-PCP14 mAbs, suggesting that conjugation of the polysaccharide to a carrier protein interferes with the development of carrier protein-specific Ab responses. Our findings provide molecular insights into the maturation of Ab responses driven by booster doses of glycoconjugate. This has fundamental implications for the design of glycoconjugate vaccines, especially where the development of Ab response against the carrier protein is also crucial.
糖缀合物疫苗通过募集 T 细胞帮助来引发针对多糖的强烈抗体反应。需要多次接种糖缀合物疫苗才能诱导持久的免疫。针对多糖抗体反应的特征已被先前报道。然而,糖缀合物加强免疫对针对多糖和载体蛋白的抗体库的影响仍知之甚少。在这项研究中,我们使用临床上相关的肺炎球菌荚膜多糖 14 型(PCP14)与交叉反应物质 197(CRM197)缀合作为模型糖缀合抗原(PCP14-CRM197)。我们对用一剂或三剂 PCP14-CRM197 免疫后针对 PCP14 和 CRM197 产生的小鼠 mAb 进行了全面的序列分析。对配对的 Ig H 和 L 链转录本的分析表明,针对 PCP14 的 Ab 库受到了极大的限制。从不同小鼠中产生的针对多糖的 mAb 中在相同位置反复出现五个替换突变,为 PCP14 特异性 B 细胞中的抗原驱动选择提供了证据。观察到趋同进化,其中不同的 V(D)J 重排导致针对 PCP14 的 mAb 中的 CDR3 相同或几乎相同。缺乏 DH 编码氨基酸的 Abs 主导了针对 PCP14 的 Ab 反应。相比之下,针对 CRM197 的 Ab 反应非常多样化,与针对 PCP14 的 mAb 相比,突变较少,这表明多糖与载体蛋白的缀合会干扰载体蛋白特异性 Ab 反应的发展。我们的发现为糖缀合物加强剂量驱动的 Ab 反应成熟提供了分子见解。这对于糖缀合物疫苗的设计具有根本意义,特别是在针对载体蛋白的 Ab 反应的发展也至关重要的情况下。